title: Therapeutic termination of second trimester pregnancy with vaginal misoprostol.
abstract: OBJECTIVE
  To evaluate the efficacy of vaginal misoprostol in therapeutic termination of second trimester pregnancy with a live fetus.
  
  
  METHODS
  Prospective descriptive study.
  
  
  METHODS
  Maharaj Nakorn Chiang Mai Hospital, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University.
  
  
  METHODS
  Pregnant women meeting the inclusion criteria including 1) pregnancy with a live fetus, 2) gestational age of 14-28 weeks, 3) having an indication for therapeutic termination, 4) Bishop's score of < or = 4, 5) absence of uterine contraction and leakage of amniotic fluid, 6) no previous classical uterine scar and 7) no contraindication for misoprostol such as hypersensitivity.
  
  
  METHODS
  400 microgram misoprostol gel intravagina every 12 hours.
  
  
  METHODS
  Mean induction-delivery time, mean abortion time, maternal side effects.
  
  
  RESULTS
  Sixty eight pregnant women were recruited into the study. The mean induction-delivery time was 35.58 +/- 34.13 hours, mean abortion time was 35.80 +/- 34.13 minutes. Fever was the most common side effect occuring in about two-third of the patients, but no serious maternal complication was observed.
  
  
  CONCLUSIONS
  400 microgram vaginal misoprostol is effective for therapeutic termination of second trimester pregnancy with no serious side effects. However, the response to this treatment was markedly varied from patient to patient.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Pongsatha
authors.forename: T
authors.initials: T
authors.lastname: Tongsong
authors.forename: O
authors.initials: O
authors.lastname: Suwannawut
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000032:Abortion, Therapeutic; D000282:Administration, Intravaginal; D000328:Adult; D005260:Female; D005782:Gels; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D005782:Gels; D016595:Misoprostol